Skip to main content

Table 1 The SPATS2L expression characteristics of AM patients between low and high group

From: Spermatogenesis associated serine rich 2 like plays a prognostic factor and therapeutic target in acute myeloid leukemia by regulating the JAK2/STAT3/STAT5 axis

Variables

SPATS2L expression

P value

Low group

High group

Number, n (%)

111 (50%)

111 (50%)

 

Age, median(range)

46 (15,80)

52 (14,82)

0.012

Female, n (%)

45 (40.5)

56 (50.5)

0.178

WBC1, median(range)

21.70 (0.2,453.2)

20.8 (0.7,229.90)

0.284

HB2, median(range)

85.0 (33.5,141.0)

80.0 (37.4,135)

0.090

PLT3, median(range)

33 (2,556)

62 (4,778)

0.001

BM4 blast, median(range)%

70 (20,98)

69 (17.5,96.65)

0.810

FAB5 type

  

0.037

 M0

8 (7.2)

13 (11.7)

 

 M1

17 (15.3)

8 (7.2)

 

 M2

53 (47.7)

40 (36.0)

 

 M4

6 (5.4)

5 (4.5)

 

 M5

23 (20.7)

40 (36)

 

 M6

2 (1.8)

4 (3.6)

 

Karyotype risk6, n (%)

  

0.154

 Favorable

3 (2.7)

2 (1.8)

 

 Intermediate

96 (80.5)

104 (93.7)

 

 Unfavorable

7 (16.3)

2 (1.8)

 

Gene mutation

 FLT3-ITD

18 (16.2)

26 (23.4)

0.239

 NPM1

24 (21.6)

38 (34.2)

0.052

 CEBPADM7

19 (17.1)

13 (11.7)

0.122

 IDH1

5 (4.5)

14 (12.6)

0.053

 IDH2

9 (8.1)

12 (10.8)

0.647

 DNMT3A

7 (6.3)

16 (14.4)

0.076

Treatment protocols8

  

0.352

 DA or IA

82 (76.6)

73 (70.2)

 

 HAA

25 (23.4)

30 (28.8)

 

Clinical event

 Complete remission rate (%)

85 (81.7)

74 (73.3)

0.181

 Relapse rate (%)

21 (25)

39 (52.7)

0.001

 Death rate (%)

41 (36.9)

57 (52.3)

0.03

  1. 1WBC, white blood cell; 2HB, hemoglobin; 3PLT, platelet counts; 4BM, bone marrow; 5FAB, French American British classification systems. 6Karyotype Risk, Favorable subgroup comprised t(8;21)/AML1-ETO, inv16 or t(16;16)(p13.1;q22)/CBFb-MYH11,CEPRADM, NPM1 without FLT3-ITD or FLT3-ITDlow. Adverse group consisted of t (9;22), inv(3)/t(3;3), -5, -7, del (5q), del(7p), 11q23 and complex translocations. Intermediate subtype contained cytogenetically normal and AML with other cytogenetic abnormalities. 7DM: Double-allele. 6The protocols used for induction therapy in different groups including donorubicin/Ara-C (DA)-based treatment group, idarubicin/Ara-C (IA)-based, and homoharringtonine/Ara-C/aclarubicin (HAA)-based treatment group
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us